Lloyd Miller

Company: Johnson & Johnson Innovative Medicine

Job title: Vice President, Immunodermatology Disease Area Leader

Seminars:

JNJ-2113 Long-Term Extension FRONTIER 2 Study: The First & Only Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor 3:30 pm

IL-23 plays a critical role in pathogenic T-cell activation in moderate-to-severe plaque psoriasis (PsO) and underpins the inflammatory response in PsO and other IL-23- mediated diseases in dermatology, rheumatology and gastroenterology JNJ-2113 is a novel oral peptide modality with a unique MoA of binding and inhibiting the IL-23R In the FRONTIER 2 52-week Long-Term Extension…Read more

day: Conference Day One